Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai Fosun Pharmaceutical (Group) Co EBITDA Margin % Related Terms
Shanghai Fosun Pharmaceutical (Group) Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co EBITDA Margin % Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) has a EBITDA Margin % of 16.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. This is 30% below median its historical median of 23.57. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's EBITDA Margin % has ranged from 15.02 to 32.76. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #414 out of 955 companies in the Drug Manufacturers industry, placing it in the top 43.4%.
Is Shanghai Fosun Pharmaceutical (Group) Co's EBITDA Margin % too high?
Shanghai Fosun Pharmaceutical (Group) Co's current EBITDA Margin % of 16.42% is 30% below median its 10-year median of 23.57. Over the past 10 years, this metric has ranged from a low of 15.02 to a high of 32.76. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Shanghai Fosun Pharmaceutical (Group) Co's value of 16.42% is 32% above this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #414 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #414 out of 955 companies for EBITDA Margin %. This puts Shanghai Fosun Pharmaceutical (Group) Co in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Shanghai Fosun Pharmaceutical (Group) Co's value of 16.42% is 32% above this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own EBITDA Margin % has ranged from 15.02 to 32.76 over the past decade. While the company's 10-year median is 23.57 vs. the industry median of 12.44, Shanghai Fosun Pharmaceutical (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current EBITDA Margin % of 16.42% is 32% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current EBITDA Margin % is 16.42%, which is 30% below median its own 10-year median of 23.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥27.07, compared to a current price of ¥21.21 — trading 21.6% below its estimated fair value. The current EBITDA Margin % is 16.42%, which is 30% below median its 10-year median of 23.57 and 32% above the Drug Manufacturers industry median of 12.44. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196), the current EBITDA Margin % is 16.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of ¥21.21 is trading 21.6% below its estimated GF Value™ of ¥27.07.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600196:
EBITDA Margin %: 16.42% (30% below median its 10-year median of 23.57)
GF Value™: ¥27.07 vs. price of ¥21.21 (21.6% below fair value)
Industry Position: 32% above the Drug Manufacturers median (#414 of 955)
No single metric tells the full story. See the SHSE:600196 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
76GF Score
Get the complete analysis for SHSE:600196
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600196 has been successfully added to your 
